Phase 1 N=14 Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects
Schizophrenia
Primary: Lurasidone Cmax — 50.2 ng/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=69 A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol
Hyperlipidemia
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 Participants
Phase 1 N=206 A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
Solid Tumors
Primary: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 1 N=60 A Drug-drug Interaction Study of Lanabecestat (LY3314814) in Healthy Participants
Healthy
Primary: Pharmacokinetics (PK) : Maximum Concentration (Cmax) of Dabigatran — 128; 148; 138 nanogram per milliliter (ng/mL)
Phase 1 N=62 Clinical Study of WT2725 in Patients With Advanced Malignancies
Cancer
Primary: Occurrence of Dose-limiting Toxicities and Adverse Events — 0; 0; 0; 0 number of occurances
Phase 1 N=31 A Study of Nivolumab Safety and Pharmacokinetics in Patients With Severe Sepsis or Septic Shock.
Severe Sepsis
Primary: Percentage of Incidence Rates of Serious Adverse Events (SAEs), Adverse Events (AEs), Immune-mediated AEs, AEs Leading to Discontinuation, and Deaths — 6.7; 43.8; 93.3…
Phase 1 N=70 A Study of LY2484595 on Pharmacokinetics in Healthy Participants
Healthy Participants
Primary: Part 1: Number of Participants With 1 or More Adverse Events (AEs) or Any Serious AEs — 7; 2; 4; 2 Participants
Phase 1 N=49 A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia
Hairy Cell Leukemia
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Phase 1 N=29 A Dose-Escalation Study in Participants With Advanced Cancer
Advanced Cancer
Primary: Number of Participants With One or More Drug-related Adverse Events — 1; 0; 1; 0 Participants
Phase 1 N=33 Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Primary: Number of Participants Experiencing an Adverse Event (AE) — 6; 6; 0; 4 Participants
Phase 1 N=104 Dose Escalation Study With MK-2206 in Patients With Locally Advanced or Metastatic Solid Tumors (MK-2206-002)
Locally Advanced Tumors · Metastatic Solid Tumors · Cancer
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 1; 0; 0 Participants
Phase 1 N=12 Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Area Under the Concentration Time Curve of Olodaterol in Plasma Over the Time Interval From 0 to 6 Hours After Drug Administration (AUC0-6)
Phase 1 N=16 Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of BI 1026706 in Healthy Male Subjects
Healthy
Primary: Area Under the Curve of BI 1026706 From 0 to the Last Quantifiable Data Point (AUC0-tz) — 921; 1580 nmol*h/L
Phase 1 N=12 Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia
Spinal Cord Injury
Primary: Safety-Number of Adverse Events — 69 Adverse events
Phase 1 N=36 A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Primary: Maximum Observed Plasma Concentration (Cmax) of Talazoparib: Alone and in Combination With Itraconazole — 2092.00; 2936.82 Picogram per milliliter (pg/mL)